Radiotracers for SPECT imaging: Current scenario and future prospects

Adak, S., Bhalla, R., Raj, K. K. Vijaya, Mandal, S., Pickett, R. and Luthra, S. K. (2012) Radiotracers for SPECT imaging: Current scenario and future prospects. Radiochimica Acta, 100 2: 95-107. doi:10.1524/ract.2011.1891

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ353928_OA.pdf Full text (open access) application/pdf 717.41KB 0

Author Adak, S.
Bhalla, R.
Raj, K. K. Vijaya
Mandal, S.
Pickett, R.
Luthra, S. K.
Title Radiotracers for SPECT imaging: Current scenario and future prospects
Journal name Radiochimica Acta   Check publisher's open access policy
ISSN 0033-8230
Publication date 2012
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1524/ract.2011.1891
Open Access Status File (Publisher version)
Volume 100
Issue 2
Start page 95
End page 107
Total pages 13
Place of publication Munich, Germany
Publisher De Gruyter Oldenbourg
Language eng
Abstract Single photon emission computed tomography (SPECT) has been the cornerstone of nuclear medicine and today it is widely used to detect molecular changes in cardiovascular, neurological and oncological diseases. While SPECT has been available since the 1980s, advances in instrumentation hardware, software and the availability of new radiotracers that are creating a revival in SPECT imaging are reviewed in this paper. The biggest change in the last decade has been the fusion of CT with SPECT, which has improved attenuation correction and image quality. Advances in collimator design, replacement of sodium iodide crystals in the detectors with cadmium zinc telluride (CZT) detectors as well as advances in software and reconstruction algorithms have all helped to retain SPECT as a much needed and used technology. Today, a wide spectrum of radiotracers is available for use in cardiovascular, neurology and oncology applications. The development of several radiotracers for neurological disorders is briefly described in this review, including [ 123I]FP-CIT (DaTSCAN ™) available for Parkinson's disease. In cardiology, while technetium-99m labeled tetrofosmin and technetium-99m labeled sestamibi have been well known for myocardial perfusion imaging, we describe a recently completed multicenter clinical study on the use of [ 123I]mIBG (AdreView ™) for imaging in chronic heart failure patients. For oncology, while bone scanning has been prevalent, newer radiotracers that target cancer mechanisms are being developed. Technetium-99m labeled RGD peptides have been reported in the literature that can be used for imaging angiogenesis, while technetium-99m labeled duramycin has been used to image apoptosis. While PET/CT is considered to be the more advanced technology particularly for oncology applications, SPECT continues to be the modality of choice and the workhorse in many hospitals and nuclear medicine centers. The cost of SPECT instruments also makes them more attractive in developing countries where the cost of a scan is still prohibitive for many patients.
Keyword 123-Iodine
Cardiovascular imaging
Neurological imaging
Nuclear medicine
Oncological imaging
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collection: Centre for Advanced Imaging Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 7 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 10 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 16 Mar 2015, 15:46:52 EST by System User on behalf of Scholarly Communication and Digitisation Service